Early and comprehensive care bundle in the elderly for acute heart failure in the emergency department: study protocol of the ELISABETH stepped-wedge cluster randomized trial

Yonathan Freund, Judith Gorlicki, Marine Cachanado, Sarah Salhi, Vanessa Lemaître, Tabassome Simon, Alexandre Mebazaa, Yonathan Freund, Judith Gorlicki, Marine Cachanado, Sarah Salhi, Vanessa Lemaître, Tabassome Simon, Alexandre Mebazaa

Abstract

Background: Acute heart failure (AHF) is one of the most common diagnoses for elderly patients in the emergency department (ED), with an admission rate above 80% and 1-month mortality around 10%. The European guidelines for the management of AHF are based on moderate levels of evidence, due to the lack of randomized controlled trials and the scarce evidence of any clinical added value of a specific treatment to improve outcomes. Recent reports suggest that the very early administration of full recommended therapy may decrease mortality. However, several studies have highlighted that elderly patients often received suboptimal treatment. Our hypothesis is that an early care bundle that comprises early and comprehensive management of symptoms, along with prompt detection and treatment of precipitating factors should improve AHF outcome in elderly patients.

Methods/design: ELISABETH is a stepped-wedge, cluster randomized controlled, clinical trial in 15 emergency departments in France recruiting all patients aged 75 years and older with a diagnosis of AHF. The tested intervention is a care bundle with a checklist that mandates detection and early treatment of AHF precipitating factors, early and intensive treatment of congestion with intravenously administered nitrate boluses, and application of other recommended treatment (low-dose diuretics, non-invasive ventilation when indicated, and preventive low-molecular-weight heparin). Each center is randomized to the order in which they will switch from a "control period" to an "intervention period." All centers begin the trials with the control period for 2 weeks, then after each 2-week step a new center will enter the intervention period. At the end of the trial, all clusters will receive the intervention regimen. The primary outcome is the number of days alive and out of the hospital at 30 days.

Discussion: If our hypothesis is confirmed, this trial will strengthen the level of evidence of AHF guidelines and stress the importance of the associated early and comprehensive treatment of precipitating factors. This trial could be the first to report a reduction in short-term morbidity and mortality in elderly AHF patients.

Trial registration: ClinicalTrials.gov, ID: NCT03683212. Prospectively registered on 25 September 2018.

Keywords: Acute heart failure; Elderly; Emergency department.

Conflict of interest statement

Ethics approval and consent to participate

Informed consent will be obtained from all study participants whenever possible. If the patient is unable to consent, informed consent from a relative will be obtained. If there is no relative, an emergency consent could be obtained. In all cases, the patient’s consent will be obtained as soon as their condition allows it. An Institutional Review Board authorized the study (Comité de Protection des Personnes SOOM 2, ID-RCB: 2018-AO1139–46, 6 September 2018) for all participating centers, as this trial will be conducted in France only.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Handover sheet with checklist for acute heart failure (AHF) management

References

    1. Arrigo M, Parissis JT, Akiyama E, Mebazaa A. Understanding acute heart failure: pathophysiology and diagnosis. Eur Heart J Suppl. 2016;18:G11–G18. doi: 10.1093/eurheartj/suw044.
    1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail. 2008;10:933–989. doi: 10.1016/j.ejheart.2008.08.005.
    1. Ezekowitz JA, Bakal JA, Kaul P, Westerhout CM, Armstrong PW. Acute heart failure in the emergency department: short- and long-term outcomes of elderly patients with heart failure. Eur J Heart Fail. 2008;10:308–314. doi: 10.1016/j.ejheart.2008.01.014.
    1. Logeart D, Isnard R, Resche-Rigon M, Seronde M-F, de Groote P, Jondeau G, et al. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study. Eur J Heart Fail. 2013;15:465–476. doi: 10.1093/eurjhf/hfs189.
    1. Teixeira A, Parenica J, Park JJ, Ishihara S, AlHabib KF, Laribi S, et al. Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort. Eur J Heart Fail. 2015;17:1114-23.
    1. Storrow AB, Jenkins CA, Self WH, Alexander PT, Barrett TW, Han JH, et al. The burden of acute heart failure on U.S. emergency departments. JACC Heart Fail. 2014;2:269–277. doi: 10.1016/j.jchf.2014.01.006.
    1. Freund Y, Delerme S, Boddaert J, Baker E, Riou B, Ray P. Isosorbide dinitrate bolus for heart failure in elderly emergency patients: a retrospective study. Eur J Emerg Med Off J Eur Soc Emerg Med. 2011;18:272–275. doi: 10.1097/MEJ.0b013e328345d72a.
    1. Packer M, O’Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017;376:1956–1964. doi: 10.1056/NEJMoa1601895.
    1. Cannon JA, McKean AR, Jhund PS, McMurray JJV. What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? Open Heart. 2015;2:e000283. doi: 10.1136/openhrt-2015-000283.
    1. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–1847. doi: 10.1093/eurheartj/ehs104.
    1. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17:544–558. doi: 10.1002/ejhf.289.
    1. Collins SP, Storrow AB, Levy PD, Albert N, Butler J, Ezekowitz JA, et al. Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group. Acad Emerg Med Off J Soc Acad Emerg Med. 2015;22:94–112. doi: 10.1111/acem.12538.
    1. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351:389–393. doi: 10.1016/S0140-6736(97)08417-1.
    1. Sharon A, Shpirer I, Kaluski E, Moshkovitz Y, Milovanov O, Polak R, et al. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol. 2000;36:832–837. doi: 10.1016/S0735-1097(00)00785-3.
    1. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805. doi: 10.1056/NEJMoa1005419.
    1. Mebazaa A, Longrois D, Metra M, Mueller C, Richards AM, Roessig L, et al. Agents with vasodilator properties in acute heart failure: how to design successful trials. Eur J Heart Fail. 2015;17:652–664. doi: 10.1002/ejhf.294.
    1. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008;359:142–151. doi: 10.1056/NEJMoa0707992.
    1. Lemachatti N, Philippon A-L, Bloom B, Hausfater P, Riou B, Ray P, et al. Temporal trends in nitrate utilization for acute heart failure in elderly emergency patients: a single-centre observational study. Arch Cardiovasc Dis. 2016;109:449–456. doi: 10.1016/j.acvd.2016.01.014.
    1. Gorlicki J, Minka H, Chouihed T, Thibaut D, Feral-Pierssens A-L, Laribi S, et al. Low compliance to guidelines in the management of acute heart failure in emergency elderly patients : a multicenter pilot prospective study. Eur J Emerg Med. In press.
    1. Diaz A, Ciocchini C, Esperatti M, Becerra A, Mainardi S, Farah A. Precipitating factors leading to decompensation of chronic heart failure in the elderly patient in South-American community hospital. J Geriatr Cardiol JGC. 2011;8:12–14. doi: 10.3724/SP.J.1263.2011.00012.
    1. Berkovitch A, Maor E, Sabbag A, Chernomordik F, Elis A, Arbel Y, et al. Precipitating factors for acute heart failure hospitalization and long-term survival. Medicine (Baltimore). 2015;94:e2330.
    1. Arrigo M, Tolppanen H, Sadoune M, Feliot E, Teixeira A, Laribi S, et al. Effect of precipitating factors of acute heart failure on readmission and long-term mortality. ESC Heart Fail. 2016;3:115–121. doi: 10.1002/ehf2.12083.
    1. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet Lond Engl. 2013;381:29–39. doi: 10.1016/S0140-6736(12)61855-8.
    1. Peacock WF, Emerman C, Costanzo MR, Diercks DB, Lopatin M, Fonarow GC. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail Greenwich Conn. 2009;15:256–264. doi: 10.1111/j.1751-7133.2009.00112.x.
    1. Mebazaa A, Pang PS, Tavares M, Collins SP, Storrow AB, Laribi S, et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J. 2010;31:832–841. doi: 10.1093/eurheartj/ehp458.
    1. Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69:3042–3051. doi: 10.1016/j.jacc.2017.04.042.
    1. Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ. 2015;350:h391. doi: 10.1136/bmj.h391.
    1. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JGF, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15:1082–1094. doi: 10.1093/eurjhf/hft095.
    1. Allen LA, Hernandez AF, O’Connor CM, Felker GM. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol. 2009;53:2248–2258. doi: 10.1016/j.jacc.2008.12.079.
    1. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) Eur Heart J. 2016;37:267–315. doi: 10.1093/eurheartj/ehv320.
    1. Teixeira A, Arrigo M, Tolppanen H, Gayat E, Laribi S, Metra M, et al. Management of acute heart failure in elderly patients. Arch Cardiovasc Dis. 2016;109:422–430. doi: 10.1016/j.acvd.2016.02.002.
    1. Christ M, Mueller C. Editor’s choice—Call to action: initiation of multidisciplinary care for acute heart failure begins in the emergency department. Eur Heart J Acute Cardiovasc Care. 2016;5:141–149. doi: 10.1177/2048872615581501.
    1. Januzzi JL, Felker GM. Door-to-furosemide therapy in the ED: new quality metric or just a piece of the puzzle? J Am Coll Cardiol. 2017;69:3052–3054. doi: 10.1016/j.jacc.2017.05.009.
    1. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–1377. doi: 10.1056/NEJMoa010307.
    1. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis*. Crit Care Med. 2014;42:625–631. doi: 10.1097/CCM.0000000000000026.

Source: PubMed

3
Abonner